ImmunityBio, Inc.
IBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,328,638 | $2,344,890 | $2,568,018 | $1,785,119 |
| - Cash | $60,241 | $137,658 | $60,660 | $143,428 |
| + Debt | $41,446 | $535,316 | $526,274 | $504,166 |
| Enterprise Value | $2,309,843 | $2,742,548 | $3,033,632 | $2,145,857 |
| Revenue | $32,061 | $26,425 | $16,517 | $7,552 |
| % Growth | 21.3% | 60% | 118.7% | – |
| Gross Profit | $27,933 | $26,289 | $16,459 | $7,552 |
| % Margin | 87.1% | 99.5% | 99.6% | 100% |
| EBITDA | -$35,774 | -$59,541 | -$97,206 | -$40,120 |
| % Margin | -111.6% | -225.3% | -588.5% | -531.3% |
| Net Income | -$67,253 | -$92,555 | -$129,646 | -$59,162 |
| % Margin | -209.8% | -350.3% | -784.9% | -783.4% |
| EPS Diluted | -0.071 | -0.1 | -0.15 | -0.09 |
| % Growth | 29% | 33.3% | -66.7% | – |
| Operating Cash Flow | -$68,907 | -$79,746 | -$85,905 | -$85,144 |
| Capital Expenditures | $0 | -$1,081 | -$1,121 | -$2,111 |
| Free Cash Flow | -$68,907 | -$80,827 | -$87,026 | -$87,255 |